SCHEMBL3093028

SCHEMBL3093028

CCCC[Sn](CCCC)(OC(=O)Cc1ccc(C(=O)c2ccccc2)cc1)OC(=O)Cc1ccc(C(=O)c2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.44
ALDH1A1 P00352 7/20 0.44
SRD5A2 P31213 2/20 0.43
HTT P42858 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 4/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
BDKRB2 P30411 1/20 0.40
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
KMT2A Q03164 1/20 0.38
CNR2 P34972 1/20 0.38
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3098694 0.89 ELANE (0.44) ELANEALDH1A1SRD5A2HTTRAB9A
SCHEMBL3093634 0.83 ALDH1A1 (0.48) ELANEALDH1A1SRD5A2HTTRAB9A
SCHEMBL27954088 0.76 LMNA (0.51) L3MBTL1MEN1KMT2A
SCHEMBL3092478 0.76 ALDH1A1 (0.49) ELANEALDH1A1SRD5A2HTTRAB9A
SCHEMBL3085168 0.76 ALDH1A1 (0.49) ELANEALDH1A1SRD5A2HTTRAB9A
SCHEMBL15753014 0.75 KMT2A (0.55) ELANEALDH1A1SRD5A2HTTRAB9A
SCHEMBL3098844 0.75 ELANE (0.50) ELANEALDH1A1HTTRAB9ASMN1; SMN2
SCHEMBL3086075 0.75 ALDH1A1 (0.50) ELANEALDH1A1SRD5A2HTTRAB9A
SCHEMBL27504159 0.75 CYP4F2 (0.56) ELANEALDH1A1SRD5A2HTTRAB9A
SCHEMBL3092962 0.74 ALDH1A1 (0.48) ELANEALDH1A1SRD5A2HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203496-B1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS BASF SE (DE) 2018-04-11 EP disclosed
US-8318830-B2 Photolatent catalysts based on organometallic compounds BASF SE (DE) 2012-11-27 US disclosed
US-20100234485-A1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS BASF SE (DE) 2010-09-16 US disclosed
EP-2203496-A1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS BASF SE (DE) 2010-07-07 EP disclosed
WO-2009050115-A1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS BASF SE (CH) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234485-A1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS PUF60, TST, MPST ELANE 1873/4885ALDH1A1 1432/4885SRD5A2 4506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.